# Oral vitamin C × serum urate: a small average reduction differs from gout treatment Verdict 3019 · Evidence Check Stored-material review date: Not recorded Original evidence cut-off: 2026-09-07 Review-criteria version: 1.0 Public page/material preparation date: 2026-10-22 Clinical papers were not read directly; existing review summaries were checked. No new clinical-literature search was performed. Unverified does not mean that research is absent or that there is no effect. ## Assessment scope - Population: Adults without gout and healthy adults with high urate are distinguished from established gout. Details of baseline urate, deficiency, urate-lowering medication and group composition remain unverified. - Ingredient, formulation and route: Oral single-ingredient ascorbic acid tablets/capsules are distinguished from the 2026 C-added sugar-matched drink. Naturally occurring food C, combinations, intravenous use and hesperidin coadministration are not automatically included. - Dose: Main-trial 500 mg/day and the 2026 single-agent drink’s nominal 600 mg and measured 592±12 mg are retained. The measured dispersion definition and actual exposure/adherence remain unverified. - Comparator: Placebo and the sugar-matched drink are distinguished from active comparisons involving allopurinol initiation or titration. Strata defined by prior use are not relabeled as C and active-drug allocation arms. - Measured outcome: This concerns serum urate in mg/dL or mmol/L. A concentration change does not directly establish first-onset gout, attacks, recurrence, cure or replacement of standard medication. Units are not newly converted. - Duration: 2 months and 8 weeks are distinguished from the 2026 trial’s 2 weeks. Week 1 and week 2 visits, study periods and actual dosing/post-stopping follow-up are not combined as one duration. - Questions outside this scope: Existing C54, caution, B/S/R0/I2/E+/B2/C0, disabled indicators and empty values are preserved. Historical independent-comparison wording and pooled signals do not establish completed clinical content review in this work.; The existing −0.59 mg/dL is a calculated simple change difference without its own 95% CI. CIs for each group’s change are not used as a between-group CI, and no new difference or interval is calculated.; The 20 existing allopurinol users and 20 nonusers define strata for allocation within each stratum. They are not relabeled as 20 in the C arm and 20 in the active-drug arm.; The 2026 single-agent C drink’s within-group week 1 P<.01 and absence of detected time-specific between-group differences are retained together. Model mean±SE is not relabeled as SD or CI, and the design is not relabeled as every participant receiving all four drinks.; The review’s average −0.35 mg/dL across 13 RCTs and substantial heterogeneity are retained without adding primary-trial and review participants. Serum urate is not extended into proof of preventing or curing gout or replacing standard treatment.; Existing caution concerning gastrointestinal effects of high oral doses and stone risk, kidney disease and iron overload is retained. Unverified report-specific harm collection, denominators and long-term details do not establish absence of harm or individual dosing instructions. ## Checklist items ### N01 · Which urate question is addressed? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The outcome is reduced serum urate in adults. Serum urate in mg/dL or mmol/L and gout attacks, first onset or recurrence are different questions. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original population, comparator and blood-test endpoint/time tables are needed. Gout prevention, cure or replacement of standard medication is not added. - Required materials and conditions: Direct comparison of oral single-ingredient C and serum urate in adults - Materials to obtain first: Original population, comparator and blood-test endpoint/time tables are needed. Gout prevention, cure or replacement of standard medication is not added. - Further research: Material needed: Original population, comparator and blood-test endpoint/time tables are needed. Gout prevention, cure or replacement of standard medication is not added. This records needed materials; no new research was executed. - Conditions for verification: Original records on Direct comparison of oral single-ingredient C and serum urate in adults must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Direct comparison of oral single-ingredient C and serum urate in adults is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N02 · Are tablets/capsules and C-added drinks distinguished? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The formulation distinguishes tablets/capsules from the 2026 sugar-matched C-added drink. Naturally occurring food C, combinations and IV use are not automatically included. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original product, salt, added ingredients/sugars, manufacturing, excipients and single-agent conditions are needed. Formulation equivalence is not certified. - Required materials and conditions: Products/ingredients of ascorbic acid tablets/capsules and sugar-matched added-C drinks - Materials to obtain first: Original product, salt, added ingredients/sugars, manufacturing, excipients and single-agent conditions are needed. Formulation equivalence is not certified. - Further research: Material needed: Original product, salt, added ingredients/sugars, manufacturing, excipients and single-agent conditions are needed. Formulation equivalence is not certified. This records needed materials; no new research was executed. - Conditions for verification: Original records on Products/ingredients of ascorbic acid tablets/capsules and sugar-matched added-C drinks must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Products/ingredients of ascorbic acid tablets/capsules and sugar-matched added-C drinks is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N03 · Are 500 mg and nominal 600/measured 592±12 mg retained? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: Doses are main-trial 500 mg/day and the 2026 single-agent drink’s nominal 600 mg (measured 592±12 mg). Original units/± are retained without deriving conversions or recommendations. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original measurement, dispersion definition, ingredients, administration/adherence and trial-specific dose linkage are needed. - Required materials and conditions: Trial-specific dose, measured content, frequency and exposure - Materials to obtain first: Original measurement, dispersion definition, ingredients, administration/adherence and trial-specific dose linkage are needed. - Further research: Material needed: Original measurement, dispersion definition, ingredients, administration/adherence and trial-specific dose linkage are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on Trial-specific dose, measured content, frequency and exposure must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Trial-specific dose, measured content, frequency and exposure is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N04 · Are 2 months, 8 weeks and 2 weeks retained separately? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The duration distinguishes 2 months and 8 weeks from the 2026 trial’s 2 weeks. R01 bibliography records 184 participants over 2 months. Results are not relabeled as one duration. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Each report’s original schedule, actual dosing, post-stopping course and period/time linkage are needed. - Required materials and conditions: Original-trial exposure, measurement and follow-up end points - Materials to obtain first: Each report’s original schedule, actual dosing, post-stopping course and period/time linkage are needed. - Further research: Material needed: Each report’s original schedule, actual dosing, post-stopping course and period/time linkage are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on Original-trial exposure, measurement and follow-up end points must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Original-trial exposure, measurement and follow-up end points is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N05 · Are non-gout, healthy high-urate and established-gout populations distinguished? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The population separates adults without gout or healthy high-urate adults from established gout. The existing counterview retains differences in baseline urate, deficiency, medication and applicability to gout. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original diagnosis, baseline tests, medication/deficiency, eligibility/exclusions and group tables are needed. A pooled mean is not used as every population’s value. - Required materials and conditions: Population-specific baseline urate, diagnosis, deficiency and urate medication - Materials to obtain first: Original diagnosis, baseline tests, medication/deficiency, eligibility/exclusions and group tables are needed. A pooled mean is not used as every population’s value. - Further research: Material needed: Original diagnosis, baseline tests, medication/deficiency, eligibility/exclusions and group tables are needed. A pooled mean is not used as every population’s value. This records needed materials; no new research was executed. - Conditions for verification: Original records on Population-specific baseline urate, diagnosis, deficiency and urate medication must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Population-specific baseline urate, diagnosis, deficiency and urate medication is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N06 · Are placebo, drinks and allopurinol retained as different contrasts? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The comparator separates placebo/sugar-matched drinks from direct allopurinol initiation or titration comparisons. An active-drug contrast is not relabeled as a placebo test of 0 effect. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original report/stratum-specific group conditions, drug initiation/titration, matched drinks and common care are needed. - Required materials and conditions: R01 placebo, R02 active-drug and R03 sugar-matched drink conditions - Materials to obtain first: Original report/stratum-specific group conditions, drug initiation/titration, matched drinks and common care are needed. - Further research: Material needed: Original report/stratum-specific group conditions, drug initiation/titration, matched drinks and common care are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on R01 placebo, R02 active-drug and R03 sugar-matched drink conditions must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on R01 placebo, R02 active-drug and R03 sugar-matched drink conditions is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N07 · Can diet, urate medication, coadministration and adherence be separated? Verification status: Unverified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The account retains applicability differences involving baseline urate medication, deficiency and sugary drinks. Detailed actual group-specific diet, medication and adherence remain unverified here. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original maintained/changed medication, diet, common care, adherence and discontinuation records are needed. An isolated C effect is not established. - Required materials and conditions: Baseline medication, treatment changes, diet/drinks and actual exposure - Materials to obtain first: Original maintained/changed medication, diet, common care, adherence and discontinuation records are needed. An isolated C effect is not established. - Further research: Material needed: Original maintained/changed medication, diet, common care, adherence and discontinuation records are needed. An isolated C effect is not established. This records needed materials; no new research was executed. - Conditions for verification: Original records on Baseline medication, treatment changes, diet/drinks and actual exposure must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Baseline medication, treatment changes, diet/drinks and actual exposure is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N08 · What are the R01 sample of 184 and group analysis denominators? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: R01 records 184 participants; group allocation and final analysis sample sizes remain unverified. Group counts, completers and attrition are not newly created. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original group flow, analysis/completion, missing endpoints and exclusion/missingness rules are needed. - Required materials and conditions: Huang trial allocation, analysis, completion and urate denominators - Materials to obtain first: Original group flow, analysis/completion, missing endpoints and exclusion/missingness rules are needed. - Further research: Material needed: Original group flow, analysis/completion, missing endpoints and exclusion/missingness rules are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on Huang trial allocation, analysis, completion and urate denominators must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Huang trial allocation, analysis, completion and urate denominators is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N09 · What are R01 group-specific changes and CIs? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The original result is C change −0.5 mg/dL (95% CI −0.6, −0.3), placebo +0.09 (−0.05, 0.2), between-group P<.0001. Group-change CIs are not transferred into a between-group difference CI. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original change/variance, groups/time points, denominators and adjustment/test tables are needed. - Required materials and conditions: Separate C/placebo change intervals and the between-group test - Materials to obtain first: Original change/variance, groups/time points, denominators and adjustment/test tables are needed. - Further research: Material needed: Original change/variance, groups/time points, denominators and adjustment/test tables are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on Separate C/placebo change intervals and the between-group test must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Separate C/placebo change intervals and the between-group test is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N10 · Is the existing −0.59 calculation distinguished from its missing CI? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The stored change difference −0.59 mg/dL is a calculation without its own 95% CI. It is not a new calculation or certification of an adjusted/precise effect in this work. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original between-group estimates, variance, CIs and model are needed. Group-specific CIs are not reused or reverse-calculated. - Required materials and conditions: Historical simple change difference and original between-group estimate/CI - Materials to obtain first: Original between-group estimates, variance, CIs and model are needed. Group-specific CIs are not reused or reverse-calculated. - Further research: Material needed: Original between-group estimates, variance, CIs and model are needed. Group-specific CIs are not reused or reverse-calculated. This records needed materials; no new research was executed. - Conditions for verification: Original records on Historical simple change difference and original between-group estimate/CI must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Historical simple change difference and original between-group estimate/CI is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N11 · Are R01 allocation, blinding and prior urate hierarchy known? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: R01 is a double-blind placebo RCT, but prior registration/SAP remain unverified. A design label does not certify every method or prespecification. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original methods, registration, plans and all endpoints/time points are needed. No formal RoB2/GRADE is produced. - Required materials and conditions: Sequence, concealment, blinding, registration/SAP and primary endpoint - Materials to obtain first: Original methods, registration, plans and all endpoints/time points are needed. No formal RoB2/GRADE is produced. - Further research: Material needed: Original methods, registration, plans and all endpoints/time points are needed. No formal RoB2/GRADE is produced. This records needed materials; no new research was executed. - Conditions for verification: Original records on Sequence, concealment, blinding, registration/SAP and primary endpoint must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Sequence, concealment, blinding, registration/SAP and primary endpoint is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N12 · Are the two R02 allopurinol strata kept distinct from treatment arms? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: R02 records 40 participants: 20 existing allopurinol users and 20 nonusers, with allocation within each stratum. These 20/20 are not relabeled as C-arm/active-control counts. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Stratum-specific drug initiation/titration, group allocation/analysis, baseline urate and flow tables are needed. Participants are not summed. - Required materials and conditions: Allocation/denominators within strata of 20 prior users and 20 nonusers - Materials to obtain first: Stratum-specific drug initiation/titration, group allocation/analysis, baseline urate and flow tables are needed. Participants are not summed. - Further research: Material needed: Stratum-specific drug initiation/titration, group allocation/analysis, baseline urate and flow tables are needed. Participants are not summed. This records needed materials; no new research was executed. - Conditions for verification: Original records on Allocation/denominators within strata of 20 prior users and 20 nonusers must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Allocation/denominators within strata of 20 prior users and 20 nonusers is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N13 · What are the urate reductions in the R02 active comparison? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: R02 records reductions of 0.23 versus 1.9 mg/dL, P<.001, with the exact adjusted between-group CI unverified. The comparison shows a smaller response than allopurinol, not no C effect versus placebo. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original stratum/group, variance, model, CI and time/denominator result tables are needed. No new difference, 0 effect or flare-prevention estimate is created. - Required materials and conditions: Contrast, P value and adjusted CI for reductions of 0.23 versus 1.9 mg/dL - Materials to obtain first: Original stratum/group, variance, model, CI and time/denominator result tables are needed. No new difference, 0 effect or flare-prevention estimate is created. - Further research: Material needed: Original stratum/group, variance, model, CI and time/denominator result tables are needed. No new difference, 0 effect or flare-prevention estimate is created. This records needed materials; no new research was executed. - Conditions for verification: Original records on Contrast, P value and adjusted CI for reductions of 0.23 versus 1.9 mg/dL must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Contrast, P value and adjusted CI for reductions of 0.23 versus 1.9 mg/dL is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N14 · Are the R02 open-label design and registration citation distinct from actual plans? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The design is an open-label randomized pilot with an active comparison. ACTRN12610000545066 is reported in the paper; official registration details remain unverified. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original methods, within-stratum allocation, registration/changes and protocol/SAP are needed. A registration identifier does not establish prespecification or reading. - Required materials and conditions: Open-label pilot methods and official ACTRN history - Materials to obtain first: Original methods, within-stratum allocation, registration/changes and protocol/SAP are needed. A registration identifier does not establish prespecification or reading. - Further research: Material needed: Original methods, within-stratum allocation, registration/changes and protocol/SAP are needed. A registration identifier does not establish prespecification or reading. This records needed materials; no new research was executed. - Conditions for verification: Original records on Open-label pilot methods and official ACTRN history must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Open-label pilot methods and official ACTRN history is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N15 · Is the 2026 two-period/group design preserved? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: R03 uses randomized drink comparisons with two study groups and two periods; not everyone received all four drinks. It is not relabeled as a universal 4-drink crossover. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original allocation/sequence, periods, drink conditions, washout, assessments/denominators and plans are needed. - Required materials and conditions: HesperidrinC groups/periods, drinks and crossover/allocation conditions - Materials to obtain first: Original allocation/sequence, periods, drink conditions, washout, assessments/denominators and plans are needed. - Further research: Material needed: Original allocation/sequence, periods, drink conditions, washout, assessments/denominators and plans are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on HesperidrinC groups/periods, drinks and crossover/allocation conditions must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on HesperidrinC groups/periods, drinks and crossover/allocation conditions is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N16 · Are 43 assigned, 40 analysed and 20 each for C/control distinguished? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: R03 records 43 assigned→40 analysed; 20 each for C and control drinks. Additional combination drinks, periods or people are not added and attrition is not calculated. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original group/period flow, endpoint denominators, missingness/exclusions and same-participant linkage are needed. - Required materials and conditions: R03 allocation, analysis and single-agent drink contrast denominators - Materials to obtain first: Original group/period flow, endpoint denominators, missingness/exclusions and same-participant linkage are needed. - Further research: Material needed: Original group/period flow, endpoint denominators, missingness/exclusions and same-participant linkage are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on R03 allocation, analysis and single-agent drink contrast denominators must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on R03 allocation, analysis and single-agent drink contrast denominators is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N17 · Are time-specific R03 model mean±SE values preserved? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: R03 records C 6.02±.20→5.54±.20 (week 1)→5.71±.20 (week 2); control 5.86±.20→5.76±.20→5.86±.20, as model mean±SE. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original units, model, adjustment, time/group, denominators and all contrasts are needed. SE is not relabeled as SD/CI and differences are not calculated. - Required materials and conditions: C/control baseline, week 1 and week 2 model means/SE - Materials to obtain first: Original units, model, adjustment, time/group, denominators and all contrasts are needed. SE is not relabeled as SD/CI and differences are not calculated. - Further research: Material needed: Original units, model, adjustment, time/group, denominators and all contrasts are needed. SE is not relabeled as SD/CI and differences are not calculated. This records needed materials; no new research was executed. - Conditions for verification: Original records on C/control baseline, week 1 and week 2 model means/SE must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on C/control baseline, week 1 and week 2 model means/SE is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N18 · Are within-C P values distinguished from undetected between-drink differences? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: R03 retains within-C week 1 P<.01 alongside no detected time-specific between-group difference in the original account. It is not counted as positive between-group replication equivalent to the early RCT. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original between-group estimates/CIs, multiplicity, model and all time points are needed. Within-group significance is not converted into a placebo effect, equivalence or precise null effect. - Required materials and conditions: Within-group week 1 test and time-specific control contrasts - Materials to obtain first: Original between-group estimates/CIs, multiplicity, model and all time points are needed. Within-group significance is not converted into a placebo effect, equivalence or precise null effect. - Further research: Material needed: Original between-group estimates/CIs, multiplicity, model and all time points are needed. Within-group significance is not converted into a placebo effect, equivalence or precise null effect. This records needed materials; no new research was executed. - Conditions for verification: Original records on Within-group week 1 test and time-specific control contrasts must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Within-group week 1 test and time-specific control contrasts is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N19 · Are C+hesperidin and observational diet excluded from single-agent effects? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The existing explanation excludes C+hesperidin and observational diet from single-agent confirmation. A combination in the paper title is not copied into an isolated effect. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original drink ingredients, allocation/periods, single-agent contrasts and distinction from combination/observational material are needed. - Required materials and conditions: Original contrasts for single-agent drinks versus combinations/natural diet - Materials to obtain first: Original drink ingredients, allocation/periods, single-agent contrasts and distinction from combination/observational material are needed. - Further research: Material needed: Original drink ingredients, allocation/periods, single-agent contrasts and distinction from combination/observational material are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on Original contrasts for single-agent drinks versus combinations/natural diet must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Original contrasts for single-agent drinks versus combinations/natural diet is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N20 · Are R03 official registration hierarchy and the paper-reported number distinguished? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The registration/citation record retains the paper-reported NCT04316390 identifier, while official history, primary hierarchy and time-point correspondence remain unverified. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original registration, changes, plans and analysis tables are needed. Current registration reading, compliance or prespecification is not certified. - Required materials and conditions: Official NCT04316390 change history and primary endpoints/time points - Materials to obtain first: Original registration, changes, plans and analysis tables are needed. Current registration reading, compliance or prespecification is not certified. - Further research: Material needed: Original registration, changes, plans and analysis tables are needed. Current registration reading, compliance or prespecification is not certified. This records needed materials; no new research was executed. - Conditions for verification: Original records on Official NCT04316390 change history and primary endpoints/time points must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Official NCT04316390 change history and primary endpoints/time points is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N21 · Is the pooled report of 13 RCTs kept distinct from a new primary trial? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: Bibliography-only R04 retains an average −0.35 mg/dL across 13 RCTs with substantial heterogeneity. Included-trial counts come from the original summary and are not new certification of unique trials or independent replication. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original inclusion/extraction tables, model, CIs, denominators and shared-trial/report links are needed. Review and primary-trial participants are not summed. - Required materials and conditions: Juraschek review included/shared trials, extraction and heterogeneity - Materials to obtain first: Original inclusion/extraction tables, model, CIs, denominators and shared-trial/report links are needed. Review and primary-trial participants are not summed. - Further research: Material needed: Original inclusion/extraction tables, model, CIs, denominators and shared-trial/report links are needed. Review and primary-trial participants are not summed. This records needed materials; no new research was executed. - Conditions for verification: Original records on Juraschek review included/shared trials, extraction and heterogeneity must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Juraschek review included/shared trials, extraction and heterogeneity is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N22 · Are differences by disease, baseline status and medication retained? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The original rationale retains mixed gout/high-urate results, while the counterview retains baseline and medication applicability limits. Findings are not simply merged as identical replication of one question. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original disease/baseline, formulation, duration, medication-specific effects/denominators and prespecified subgroups/interactions are needed. - Required materials and conditions: Directness for gout/non-gout, high urate, deficiency and medication - Materials to obtain first: Original disease/baseline, formulation, duration, medication-specific effects/denominators and prespecified subgroups/interactions are needed. - Further research: Material needed: Original disease/baseline, formulation, duration, medication-specific effects/denominators and prespecified subgroups/interactions are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on Directness for gout/non-gout, high urate, deficiency and medication must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Directness for gout/non-gout, high urate, deficiency and medication is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N23 · Are urate units, measurement and analysis sets distinguished? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The primary endpoint is serum urate in mg/dL or mmol/L. Original units are not converted and serum concentrations are not relabeled as flare outcomes. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original assay, units, blood sampling/time points, baseline adjustment, variance and estimand are needed. - Required materials and conditions: mg/dL, mmol/L, baseline/change values and measurement/adjustment - Materials to obtain first: Original assay, units, blood sampling/time points, baseline adjustment, variance and estimand are needed. - Further research: Material needed: Original assay, units, blood sampling/time points, baseline adjustment, variance and estimand are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on mg/dL, mmol/L, baseline/change values and measurement/adjustment must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on mg/dL, mmol/L, baseline/change values and measurement/adjustment is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N24 · What is the original impact of missingness, attrition and selective reporting? Verification status: Unverified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: R01 unverified final group sample sizes, R02 within-stratum allocation and R03 allocation/analysis records are distinguished. Detailed missingness/exclusion rules remain unverified here. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Flow, attrition/exclusions, missing-data handling, all planned time points and sensitivity material are needed. - Required materials and conditions: Group/stratum/period missingness, discontinuation, denominators and handling - Materials to obtain first: Flow, attrition/exclusions, missing-data handling, all planned time points and sensitivity material are needed. - Further research: Material needed: Flow, attrition/exclusions, missing-data handling, all planned time points and sensitivity material are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on Group/stratum/period missingness, discontinuation, denominators and handling must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Group/stratum/period missingness, discontinuation, denominators and handling is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N25 · Are first-onset gout, recurrence, cure and drug replacement kept separate? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The existing explanation treats clinical gout as a separate question. Urate reduction or active-drug comparisons are not proof of first onset, recurrence, cure or drug replacement. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Direct tests of attacks, first onset, recurrence or drug replacement are separately needed. Other verdicts/research are not newly accessed here. - Required materials and conditions: Direct comparison of serum urate and clinical gout events - Materials to obtain first: Direct tests of attacks, first onset, recurrence or drug replacement are separately needed. Other verdicts/research are not newly accessed here. - Further research: Material needed: Direct tests of attacks, first onset, recurrence or drug replacement are separately needed. Other verdicts/research are not newly accessed here. This records needed materials; no new research was executed. - Conditions for verification: Original records on Direct comparison of serum urate and clinical gout events must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Direct comparison of serum urate and clinical gout events is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N26 · Are four company-involvement pathways and the three trials retained separately? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: R01 funding/manufacturer involvement is unverified; R02 records HRC New Zealand support with product/employee details unverified; R03 retains no external grant plus Döhler/Eckes-Granini/Ferrer in-kind support/I1. No grant is not relabeled as no company involvement. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original funding, in-kind/products, affiliations, COI and report-specific linkage are needed. Overall I2 and specific R03 I1 records are not replaced or rescored. - Required materials and conditions: Funding, in-kind/product support, employee authors and COI - Materials to obtain first: Original funding, in-kind/products, affiliations, COI and report-specific linkage are needed. Overall I2 and specific R03 I1 records are not replaced or rescored. - Further research: Material needed: Original funding, in-kind/products, affiliations, COI and report-specific linkage are needed. Overall I2 and specific R03 I1 records are not replaced or rescored. This records needed materials; no new research was executed. - Conditions for verification: Original records on Funding, in-kind/product support, employee authors and COI must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Funding, in-kind/product support, employee authors and COI is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N27 · Are 4 reports distinguished from unique trials and participants? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The 3 trial summaries and 4 citations represent primary-material/review units. Original I2/R0 records are retained; independent replication or final unique trial/participant totals are not certified here. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Registration, institutions/timing, teams, products and included/additional-report/same-sample links are needed. Final totals are null. - Required materials and conditions: Research families/shared samples of three original trials/comparisons and a review - Materials to obtain first: Registration, institutions/timing, teams, products and included/additional-report/same-sample links are needed. Final totals are null. - Further research: Material needed: Registration, institutions/timing, teams, products and included/additional-report/same-sample links are needed. Final totals are null. This records needed materials; no new research was executed. - Conditions for verification: Original records on Research families/shared samples of three original trials/comparisons and a review must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Research families/shared samples of three original trials/comparisons and a review is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N28 · Are harm collection, events and discontinuation known? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The original safety account retains high-dose gastrointestinal caution and limited event counts. Actual events, collection and causality are not newly established. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Original harm methods, severity, events/discontinuation, missingness and comparator records are needed. - Required materials and conditions: Definition, collection and events/discontinuation for diarrhoea/gastrointestinal harms - Materials to obtain first: Original harm methods, severity, events/discontinuation, missingness and comparator records are needed. - Further research: Material needed: Original harm methods, severity, events/discontinuation, missingness and comparator records are needed. This records needed materials; no new research was executed. - Conditions for verification: Original records on Definition, collection and events/discontinuation for diarrhoea/gastrointestinal harms must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Definition, collection and events/discontinuation for diarrhoea/gastrointestinal harms is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N29 · What are the safety denominators, exposure and comparators? Verification status: Unverified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The 184, 40 and 43 assigned/40 analysed do not certify safety denominators. Different periods, medication or drinks are not combined as identical harm exposure. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Group-specific safety denominators, exposure/discontinuation, events and comparator/stratum/period linkage are needed. Incidence and totals are not calculated. - Required materials and conditions: Group/stratum/period actual treatment, safety sets and exposure/events - Materials to obtain first: Group-specific safety denominators, exposure/discontinuation, events and comparator/stratum/period linkage are needed. Incidence and totals are not calculated. - Further research: Material needed: Group-specific safety denominators, exposure/discontinuation, events and comparator/stratum/period linkage are needed. Incidence and totals are not calculated. This records needed materials; no new research was executed. - Conditions for verification: Original records on Group/stratum/period actual treatment, safety sets and exposure/events must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Group/stratum/period actual treatment, safety sets and exposure/events is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N30 · What is known about kidney disease, stones, iron overload, coadministration and long-term harms? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: The product account’s caution for stone predisposition, kidney disease and iron overload is retained. Urate results are not converted into certification of kidney/stone or long-term safety. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: Vulnerable populations, coadministration, event timing/alternative causes, independent reports, longer exposure and denominators are needed. No new harm search or judgment is performed. - Required materials and conditions: Vulnerable groups, alternative causes/medication and rare/long-term/independent harms - Materials to obtain first: Vulnerable populations, coadministration, event timing/alternative causes, independent reports, longer exposure and denominators are needed. No new harm search or judgment is performed. - Further research: Material needed: Vulnerable populations, coadministration, event timing/alternative causes, independent reports, longer exposure and denominators are needed. No new harm search or judgment is performed. This records needed materials; no new research was executed. - Conditions for verification: Original records on Vulnerable groups, alternative causes/medication and rare/long-term/independent harms must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Vulnerable groups, alternative causes/medication and rare/long-term/independent harms is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N31 · Are historical HTML/PDF/abstract checks distinguished from current unread material? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: Citations retain historical abstract/institutional bibliography checks and 2026 HTML/tables/methods/PDF-text checks with a PDF-screenshot cache failure. These are historical records, not current external reading or access testing. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: External material remains unread now. A past cache failure is not converted into current paper inaccessibility, and past checks are not promoted into newly completed QA. - Required materials and conditions: Original access record, stored summary and external abstracts/full text/registration/plans - Materials to obtain first: External material remains unread now. A past cache failure is not converted into current paper inaccessibility, and past checks are not promoted into newly completed QA. - Further research: Material needed: External material remains unread now. A past cache failure is not converted into current paper inaccessibility, and past checks are not promoted into newly completed QA. This records needed materials; no new research was executed. - Conditions for verification: Original records on Original access record, stored summary and external abstracts/full text/registration/plans must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Original access record, stored summary and external abstracts/full text/registration/plans is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N32 · Are Korean/English text, empty corrections and prior calculation records preserved? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: Korean/English text, empty correction/subclaim arrays and the original −0.59 calculation label are retained. No new calculation, correction or completed English clinical review is created. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: After content review, new material, corrections or verdict changes are recorded as separate events. - Required materials and conditions: Complete originals, empty correction/subclaim records and prior calculation - Materials to obtain first: After content review, new material, corrections or verdict changes are recorded as separate events. - Further research: Material needed: After content review, new material, corrections or verdict changes are recorded as separate events. This records needed materials; no new research was executed. - Conditions for verification: Original records on Complete originals, empty correction/subclaim records and prior calculation must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Complete originals, empty correction/subclaim records and prior calculation is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ### N33 · Are original C54, axes and evidence date distinct from production? Verification status: Partly verified Reading scope: Existing Korean and English review summary, question and citations read; external abstracts, full text, registration, protocols and analysis plans unread - Current findings: C/54/caution, original assessment axes and the existing evidence date 2026-09-07 are retained. Original independence/pooled-signal wording is historical, not a new grade or certification in this work. - Why unverified: This state links partial information and gaps in the existing stored summary. External verification and clinical content review remain incomplete; it does not certify fulfilled conditions, efficacy, safety, prespecification or independence. - Reason for missing information: New material, condition revisions and verdict changes are separate events after content review. The original date is not used as a current search or external reading date. - Required materials and conditions: Original C54, caution, assessment axes and evidence date - Materials to obtain first: New material, condition revisions and verdict changes are separate events after content review. The original date is not used as a current search or external reading date. - Further research: Material needed: New material, condition revisions and verdict changes are separate events after content review. The original date is not used as a current search or external reading date. This records needed materials; no new research was executed. - Conditions for verification: Original records on Original C54, caution, assessment axes and evidence date must link to the same product, population, comparator, test, time point, stratum and denominator, distinguishing within-group and between-group findings, placebo and active drug, and direct trials and pooled reviews. - Why this condition is needed: Material on Original C54, caution, assessment axes and evidence date is needed to connect oral single-ingredient treatment, populations, comparators, urate measurement, time points, strata, denominators, precision and harms. - Application exceptions: Existing C54, caution, assessment axes and empty values are retained. Urate concentrations and gout attacks, placebo, active drug and drinks, within- and between-group findings, strata, periods and denominators are distinguished. No new change differences, CIs, unit conversions, attrition, incidence, unique totals or dosing guidance are created. - Remaining uncertainty: Group-, stratum- and time-specific denominators, CIs for the relevant contrasts and adjusted effects, prespecified hierarchy, actual exposure/adherence, shared trials/participants and long-term or harm details remain unverified. Existing calculations and historical checks are not converted into new calculations, external reading or completed clinical review in this work. - Referenced methods: Existing principles distinguish questions, direct comparisons, reports and trials, endpoints, denominators, precision and harms. - Related sources: R01, R02, R03, R04 ## Evidence and sources ### R01 Huang et al. 2005 [PubMed](https://pubmed.ncbi.nlm.nih.gov/15934094/) Materials actually read: Existing stored review summary read; external material unread Findings recorded in the summary: C change −0.5 mg/dL (95% CI −0.6, −0.3), placebo +0.09 (−0.05, 0.2), between-group P<.0001. The existing net change −0.59 mg/dL is a calculation without its own 95% CI. Record level: This concerns 184 participants over 2 months. Group allocation and final analysis denominators remain unverified. CIs for group-specific changes are not transferred into the between-group difference or a flare outcome. Independent replication: The 4 stored reports comprise 3 trial reports involving direct placebo, active allopurinol and single-agent C drink comparisons plus 1 pooled-review bibliography. Groups, strata, periods, disease and included/shared samples are distinguished; unique trial/participant totals and independent replication remain unverified. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | Stored existing review summary | Preserved copy of the complete existing review summary | Stored summary | Summary read | PMID15934094 · DOI10.1002/art.21105 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | External abstract | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID15934094 · DOI10.1002/art.21105 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | External full text | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID15934094 · DOI10.1002/art.21105 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | Registration material | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID15934094 · DOI10.1002/art.21105 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | Protocol and analysis plan | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID15934094 · DOI10.1002/art.21105 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | ### R02 Stamp et al. 2013 [PubMed](https://pubmed.ncbi.nlm.nih.gov/23681955/) Materials actually read: Existing stored review summary read; external material unread Findings recorded in the summary: Urate reductions of 0.23 versus 1.9 mg/dL, P<.001. The exact adjusted between-group 95% CI remains unverified. This compares a smaller response with allopurinol; it is not a placebo test of no C effect. Record level: Among 40 participants, allocation occurred within strata of 20 existing allopurinol users and 20 nonusers. ACTRN12610000545066 is a paper-reported identifier; official details, change history and plan compliance remain unverified. Independent replication: The 4 stored reports comprise 3 trial reports involving direct placebo, active allopurinol and single-agent C drink comparisons plus 1 pooled-review bibliography. Groups, strata, periods, disease and included/shared samples are distinguished; unique trial/participant totals and independent replication remain unverified. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | Stored existing review summary | Preserved copy of the complete existing review summary | Stored summary | Summary read | PMID23681955 · DOI10.1002/art.37925 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | External abstract | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID23681955 · DOI10.1002/art.37925 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | External full text | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID23681955 · DOI10.1002/art.37925 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | Registration material | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID23681955 · DOI10.1002/art.37925 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | Protocol and analysis plan | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID23681955 · DOI10.1002/art.37925 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | ### R03 Enderle et al. 2026 [Official source](https://link.springer.com/article/10.1007/s00394-026-03905-z) Materials actually read: Existing stored review summary read; external material unread Findings recorded in the summary: Model mean±SE: C 6.02±.20→5.54±.20 (week 1)→5.71±.20 (week 2), control 5.86±.20→5.76±.20→5.86±.20. Within-C week 1 P<.01; the original account states no detected time-specific between-group difference. Record level: The 43 assigned, 40 analysed and 20 each for C and control drinks are distinguished. Not all participants received all four drinks; C+hesperidin is excluded from single-agent confirmation. Official NCT04316390 history and hierarchy remain unverified. Independent replication: The 4 stored reports comprise 3 trial reports involving direct placebo, active allopurinol and single-agent C drink comparisons plus 1 pooled-review bibliography. Groups, strata, periods, disease and included/shared samples are distinguished; unique trial/participant totals and independent replication remain unverified. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | Stored existing review summary | Preserved copy of the complete existing review summary | Stored summary | Summary read | PMID41739218 · DOI10.1007/s00394-026-03905-z is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | External abstract | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID41739218 · DOI10.1007/s00394-026-03905-z is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | External full text | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID41739218 · DOI10.1007/s00394-026-03905-z is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | Registration material | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID41739218 · DOI10.1007/s00394-026-03905-z is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | Protocol and analysis plan | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID41739218 · DOI10.1007/s00394-026-03905-z is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | ### R04 Juraschek et al. 2011 [PubMed](https://pubmed.ncbi.nlm.nih.gov/21671418/) Materials actually read: Existing stored review summary read; external material unread Findings recorded in the summary: The existing citation records an average −0.35 mg/dL across 13 RCTs and substantial heterogeneity. Record level: PMCID PMC3169708 is retained in the original bibliography. Inclusion, extraction, shared trials, denominators and exact CIs remain unverified. The review is not added as a new primary trial and participants are not summed. Independent replication: The 4 stored reports comprise 3 trial reports involving direct placebo, active allopurinol and single-agent C drink comparisons plus 1 pooled-review bibliography. Groups, strata, periods, disease and included/shared samples are distinguished; unique trial/participant totals and independent replication remain unverified. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | Stored existing review summary | Preserved copy of the complete existing review summary | Stored summary | Summary read | PMID21671418 · DOI10.1002/acr.20519 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | External abstract | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID21671418 · DOI10.1002/acr.20519 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | External full text | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID21671418 · DOI10.1002/acr.20519 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | Registration material | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID21671418 · DOI10.1002/acr.20519 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | | Protocol and analysis plan | Original bibliographic link or needed material; external public availability/access status unverified | Unread; access not attempted | Not read | PMID21671418 · DOI10.1002/acr.20519 is retained in the existing stored record. External abstracts, full text, registration, protocols and analysis plans are unread. Historical checks or the existence of registration identifiers or a PMCID do not establish current reading, prespecification or independence. The stored-summary date is its original production timestamp; dates for unread external materials are empty. The existing evidence date is distinguished from any current external reading date. | ## Review criteria and methods These are Chamgap's own application conditions, informed by the relevant sections of official methodological guidance. They do not constitute official assessment-tool certification or a new efficacy score. - M03 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03) · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13 · Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed. - M04 [Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04) · §4.5, §4.6.1–4.6.3, MECIR C42 · Distinguish studies from reports and link them; do not omit a study solely because results are unreported. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed. - M08 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08) · §8.1–8.2.3, Table 8.2.a · Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed. - M15 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15) · §15.2.4, §15.3.1–15.3.3 · Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed. - M19 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19) · §19.1.2, §19.2.1–19.2.4 · Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed. ## What the statuses mean - Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete. - Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety. - Review incomplete: Review of existing content remains incomplete. - Met: This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work. - Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported. - Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned. - Not applicable: Used only with an application exception and reason based on the question scope. - Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work. - Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade. ## Change history 2026-10-22 · Public page/materials 1.0. Public-facing views and materials were prepared from the existing 33 items. No new clinical search, verification-status change or scoring was performed.